Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Rheumatology · Adult-onset Still's Disease

What to Expect: The Three Disease Courses of AOSD

At a Glance

Adult-onset Still's Disease (AOSD) follows three main paths: a single resolving episode (monocyclic), intermittent flares (polycyclic), or persistent joint inflammation (chronic articular). Identifying your specific pattern helps your rheumatologist tailor the best long-term treatment strategy.

One of the most common questions after an Adult-onset Still’s Disease (AOSD) diagnosis is: “What does my future look like?” Because AOSD is a heterogeneous (varied) disease, it doesn’t follow the same path for everyone. Doctors generally group patients into three classic “disease courses” based on how the condition behaves over time [1][2].

Understanding which path you are on helps your medical team decide how aggressively to treat the disease and how closely to monitor you.

1. The Monocyclic Course (Happens Once)

The monocyclic pattern is characterized by a single, self-limited episode of systemic inflammation [1].

  • What it looks like: You experience the classic triad of high fever, rash, and joint pain. Once treated, the symptoms resolve completely and do not return [2].
  • The Outlook: This is the most favorable pattern. Many patients in this group are eventually able to stop all medications and remain in permanent remission [3].

2. The Polycyclic Course (Comes and Goes in Flares)

The polycyclic (or intermittent) pattern involves multiple systemic flares alternating with periods of total remission [1][2].

  • What it looks like: Your symptoms may disappear entirely for months or even years, only to return unexpectedly. These flares often look very similar to your first episode [2].
  • The Outlook: Patients in this group may need to restart or increase treatment during flares but can often taper down during the “quiet” periods in between [1].

3. The Chronic Articular Course (Constant Joint Pain)

The chronic articular pattern is characterized by persistently active disease that primarily settles in the joints [1][2].

  • What it looks like: While the high fevers and rashes might fade away, the joint pain and swelling (arthritis) become a constant presence. This pattern most closely resembles other forms of chronic inflammatory arthritis, like rheumatoid arthritis [1][4].
  • The Outlook: This course often requires long-term “maintenance” therapy with DMARDs or biologics to prevent joint damage [5][6].

Predicting Your Path: Systemic vs. Articular

In recent years, researchers have begun simplifying these three paths into two primary “phenotypes” (categories) to help guide treatment [4][7].

Feature Systemic-Predominant Chronic Articular-Predominant
Primary Symptoms High fevers, rash, and organ involvement [8]. Persistent joint swelling and stiffness [4].
Lab Clues Extremely high ferritin and white blood cell counts [9]. More moderate ferritin; high markers like CRP [10].
Main Risk Higher risk of Macrophage Activation Syndrome (MAS) [8][11]. Risk of long-term joint damage or erosion [1].
Treatment Response Often responds very well to IL-1 inhibitors [12]. Often requires IL-6 inhibitors or conventional DMARDs [13][14].

Regardless of which course your disease takes, the goal remains the same: Clinically Inactive Disease [15]. By tracking your symptoms and labs over time, you and your doctor can identify your specific pattern and tailor your treatment to ensure the best long-term outcome [16][17].

Common questions in this guide

What are the three disease courses of Adult-onset Still's Disease?
The three classic courses of Adult-onset Still's Disease are monocyclic (a single episode that resolves permanently), polycyclic (multiple flares alternating with remission), and chronic articular (persistent joint pain and swelling).
Will my AOSD symptoms come back after the first episode?
It depends on your specific disease course. If you have the monocyclic pattern, your symptoms should resolve completely and not return. However, if you have the polycyclic pattern, symptoms may disappear for months or years before unexpectedly returning in a flare.
What is the difference between systemic and articular AOSD?
Systemic-predominant AOSD mainly causes high fevers and rashes, and it carries a higher risk of complications like Macrophage Activation Syndrome (MAS). Chronic articular-predominant AOSD primarily affects the joints, causing persistent pain and swelling similar to rheumatoid arthritis.
How is the chronic articular course of AOSD treated?
The chronic articular course often requires long-term maintenance therapy to prevent permanent joint damage. Doctors commonly use conventional DMARDs or targeted biologic medications, such as IL-6 inhibitors, to manage this specific pattern.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my initial symptoms and lab results, which of the three disease courses do you suspect I will follow?
  2. 2.Do my current lab markers (like IL-18 or ferritin) suggest a more 'systemic' or 'articular' (joint-focused) pattern?
  3. 3.If I reach a state of 'clinically inactive disease,' how long should we wait before considering a reduction or 'taper' in my medication?
  4. 4.How often should we monitor my inflammatory markers during periods when I feel completely healthy?
  5. 5.Is my persistent joint pain a sign that I am moving into the 'chronic articular' phase of the disease?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    A comprehensive review on adult onset Still's disease.

    Giacomelli R, Ruscitti P, Shoenfeld Y

    Journal of autoimmunity 2018; (93()):24-36 doi:10.1016/j.jaut.2018.07.018.

    PMID: 30077425
  2. 2

    Adult-Onset Still's Disease-A Complex Disease, a Challenging Treatment.

    Macovei LA, Burlui A, Bratoiu I, et al.

    International journal of molecular sciences 2022; (23(21)) doi:10.3390/ijms232112810.

    PMID: 36361602
  3. 3

    Cluster analysis defines four groups of Japanese patients with adult-onset Still's disease.

    Shirahama Y, Kokuzawa A, Yamauchi Y, et al.

    Modern rheumatology 2024; (34(6)):1213-1220 doi:10.1093/mr/roae023.

    PMID: 38564322
  4. 4

    Adult-onset Still's disease as a cutaneous marker of systemic disease.

    Damevska K, França K, Nikolovska S, Gucev F

    Clinics in dermatology 2019; (37(6)):668-674 doi:10.1016/j.clindermatol.2019.07.034.

    PMID: 31864446
  5. 5

    Tocilizumab for the treatment of adult-onset Still's disease.

    Castañeda S, Martínez-Quintanilla D, Martín-Varillas JL, et al.

    Expert opinion on biological therapy 2019; (19(4)):273-286 doi:10.1080/14712598.2019.1590334.

    PMID: 30827128
  6. 6

    Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review.

    Reihl Crnogaj M, Čubelić D, Babić A, et al.

    Rheumatology international 2020; (40(8)):1317-1325 doi:10.1007/s00296-020-04622-4.

    PMID: 32506202
  7. 7

    Adult-Onset Still's Disease: Clinical Aspects and Therapeutic Approach.

    Tomaras S, Goetzke CC, Kallinich T, Feist E

    Journal of clinical medicine 2021; (10(4)) doi:10.3390/jcm10040733.

    PMID: 33673234
  8. 8

    Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients.

    Ruscitti P, Rago C, Breda L, et al.

    Clinical rheumatology 2017; (36(12)):2839-2845 doi:10.1007/s10067-017-3830-3.

    PMID: 28914368
  9. 9

    Predictive factors and prognosis of macrophage activation syndrome associated with adult-onset Still's disease.

    Yang XP, Wang M, Li TF, et al.

    Clinical and experimental rheumatology 2019; (37 Suppl 121(6)):83-88.

    PMID: 31287402
  10. 10

    Adult-Onset Still's Disease: A Case Report.

    Shad I, Shafique M, Waris SA, et al.

    Cureus 2022; (14(1)):e21033 doi:10.7759/cureus.21033.

    PMID: 35155001
  11. 11

    Early identification of macrophage activation syndrome in adult-onset Still's disease: a case report and literature review.

    Long T, Xu J, Lin BZ, Li SG

    Frontiers in medicine 2025; (12()):1498928 doi:10.3389/fmed.2025.1498928.

    PMID: 39931557
  12. 12

    Efficacy and safety of biological agents in adult-onset Still's disease.

    Cavalli G, Franchini S, Aiello P, et al.

    Scandinavian journal of rheumatology 2015; (44(4)):309-14 doi:10.3109/03009742.2014.992949.

    PMID: 25656459
  13. 13

    Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still's disease.

    Kaneko Y, Takeuchi T

    Expert opinion on biological therapy 2022; (22(1)):79-85 doi:10.1080/14712598.2021.1942832.

    PMID: 34126828
  14. 14

    Interluekin-6 inhibitors for the treatment of adult-onset Still's disease.

    Kaneko Y

    Modern rheumatology 2022; (32(1)):12-15 doi:10.1093/mr/roab004.

    PMID: 34894252
  15. 15

    EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.

    Fautrel B, Mitrovic S, De Matteis A, et al.

    Annals of the rheumatic diseases 2024; (83(12)):1614-1627 doi:10.1136/ard-2024-225851.

    PMID: 39317417
  16. 16

    The latest advances in the use of biological DMARDs to treat Still's disease.

    Di Cola I, Ruscitti P

    Expert opinion on biological therapy 2024; (24(1-2)):63-75 doi:10.1080/14712598.2024.2307340.

    PMID: 38284774
  17. 17

    Toward a personalized therapy of still's disease based on immunologic endotypes: a narrative review.

    Chen PK, Wey SJ, Chen DY

    Expert review of clinical immunology 2025; (21(4)):401-412 doi:10.1080/1744666X.2025.2465406.

    PMID: 39925174

This page provides educational information about Adult-onset Still's Disease (AOSD) disease courses. It is not a substitute for professional medical advice, diagnosis, or treatment from your rheumatologist.

Get notified when new evidence is published on Adult-onset Still disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.